Journal article
The impact of quadrivalent human papillomavirus (HPV; Types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years
DR Brown, SK Kjaer, K Sigurdsson, OE Iversen, HA Mauricio, CM Wheeler, G Perez, LA Koutsky, EH Tay, P Garcia, KA Ault, SM Garland, S Leodolter, SE Olsson, GWK Tang, DG Ferris, J Paavonen, M Steben, FX Bosch, J Dillner Show all
Journal of Infectious Diseases | OXFORD UNIV PRESS INC | Published : 2009
DOI: 10.1086/597307
Abstract
Background. Human papillomavirus (HPV)-6/11/16/18 vaccine reduces the risk of HPV-6/11/16/18-related cervical intraepithelial neoplasia (CIN) 1-3 or adenocarcinoma in situ (AIS). Here, its impact on CIN1-3/AIS associated with nonvaccine oncogenic HPV types was evaluated. Methods. We enrolled 17,622 women aged 16-26 years. All underwent cervicovaginal sampling and Pap testing at regular intervals for up to 4 years. HPV genotying was performed for biopsy samples, and histological diagnoses were determined by a pathology panel. Analyses were conducted among subjects who were negative for 14 HPV types on day 1. Prespecified analyses included infection of-6 months' duration and CIN1-3/AIS due to ..
View full abstract